The study conducted by Huang et al. suggested that vitamin B6 supplementation may be beneficial in rheumatoid arthritis (RA) by reducing pro-inflammatory markers interleukin (IL-6) and tumor necrosis factor (TNFa) (Huang et al., 2010) . Interestingly, no anemic patients were included in the study despite the fact that anemia is commonly present in RA patients (Wilson et al., 2004) . We present a patient with RA, low serum vitamin B6, pyridoxine-sensitive anemia and symptoms suggestive of early pellagra in whom repletion of B6 resulted in an unexpected rise in ferritin. Based on 8 years of data, we suggest monitoring hemoglobin and ferritin levels in addition to IL-6 and TNFa as indicators of adequate treatment and to obviate the need for prolonged use of vitamin B6 at high doses.
The patient is a 65-year-old African American woman who presented with anemia, an ichthyosoform rash, diarrhea and passing of whole pills, which she was taking for hypertension, in her stool. Evaluation of the presenting symptoms led to the discovery of a normocytic anemia suggestive of anemia of chronic disease with a decreased total iron binding capacity (TIBC) of 239 (250-450 mg per 100 ml), iron saturation of 15% and elevated ferritin of 452 (10-322 ng/ml). An upper gastrointestinal study with small bowel follow-through was performed to evaluate the diarrhea and revealed normal anatomy with an abnormally fast transit time. She also had low serum vitamin B6 and B3 levels. The patient's vitamin B6 was repleted and her hemoglobin levels increased from 9 to 11.8 g per 100 ml. Over the next 7 months the patient's hemoglobin level gradually decreased, paralleling decreasing vitamin B6 and B3 levels (see Figure 1) . Repletion of vitamins B6 and B3 again resulted in an increase in hemoglobin levels with resolution of the diarrhea. An unexpected effect was an increase in ferritin to 1623 ng/ml, possibly secondary to improvement in gastrointestinal absorption of iron.
As Huang et al. predicted, this patient's chronic inflammatory state was associated with a decreased serum vitamin B6 level that contributed to the low serum B3 level and symptoms including diarrhea, malabsorption and an ichthyosoform rash. Treatment with pyridoxine resolved the patient's symptoms and anemia. Their hypothesis that vitamin B6 treatment can decrease the inflammatory markers of RA does not come without cost. Repleting vitamin B6 in this patient caused an increase in ferritin. In the FeAST trial, a positive association was made between elevated ferritin levels, inflammatory markers and mortality European Journal of Clinical Nutrition (2011) 65, 423-424 from peripheral arterial disease (DePalma et al., 2010) . In addition to possibly increasing inflammation and mortality through increased ferritin, the toxic effects of chronic, high-dose pyridoxine, such as neuropathy, warrant the need for close monitoring of pyridoxine therapy.
We would therefore like to raise the following question: Given the prevalence of anemia in patients with RA, should hemoglobin and ferritin, in addition to IL-6 and TNFa, be used as indicators of adequate pyridoxine treatment? In the pursuit of decreasing inflammatory markers, we suggest stopping the administration of pyridoxine once the hemoglobin level reaches a tolerable level of 10-12 g per 100 ml. This will prevent excessive pyridoxine administration and a deleterious rise in ferritin levels.
